Celldex Therapeutics (CLDX) Interest & Investment Income (2012 - 2026)

Celldex Therapeutics' Interest & Investment Income history runs 15 years deep, the most recent figure standing at $5.8 million for Q1 2026.

• In Q1 2026, Interest & Investment Income fell 35.7% year-over-year to $5.8 million; the TTM figure through Mar 2026 stood at $25.4 million (down 33.74% YoY), while the FY2025 annual figure was $28.6 million, down 23.12% from the prior year.
• Interest & Investment Income was $5.8 million for Q1 2026 at Celldex Therapeutics, down from $5.8 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $10.5 million in Q2 2024 to a low of $207000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $5.2 million across 5 years, with a median of $5.8 million in 2026.
• The sharpest annual moves came in 2023 and 2026: Interest & Investment Income surged 1402.42% in 2023, then tumbled 35.7% in 2026.
• A 5-year view of Interest & Investment Income shows it stood at $1.4 million in 2022, then soared by 209.08% to $4.3 million in 2023, then surged by 106.78% to $8.9 million in 2024, then slumped by 34.68% to $5.8 million in 2025, then dropped by 1.47% to $5.8 million in 2026.
• The last three Interest & Investment Income figures came in at $5.8 million (Q1 2026), $5.8 million (Q4 2025), and $6.6 million (Q3 2025), per Business Quant data.